Michaela A E Arndt Selected Research

ranpirnase (Pannon)

11/2017	Highly efficient destruction of squamous carcinoma cells of the head and neck by photochemical internalization of Ranpirnase.
5/2015	Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
2/2015	An EGF receptor targeting Ranpirnase-diabody fusion protein mediates potent antitumour activity in vitro and in vivo.
1/2015	A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.
10/2014	A fusogenic dengue virus-derived peptide enhances antitumor efficacy of an antibody-ribonuclease fusion protein targeting the EGF receptor.
6/2008	Antibody-targeted RNase fusion proteins (immunoRNases) for cancer therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michaela A E Arndt Research Topics

Disease

13	Neoplasms (Cancer) 11/2017 - 10/2003
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2016 - 12/2003
2	Head and Neck Neoplasms (Head and Neck Cancer) 10/2014 - 01/2014
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2017
1	Squamous Cell Carcinoma of Head and Neck 11/2017
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2016
1	Burkitt Lymphoma (Burkitt's Lymphoma) 03/2016
1	Lymphoma (Lymphomas) 01/2015
1	Leukemia 01/2015
1	Hematologic Neoplasms (Hematological Malignancy) 01/2015
1	Infections 04/2013
1	Encephalitis (Encephalitis, Rasmussen) 02/2011
1	Mesothelioma 06/2008
1	B-Cell Lymphoma (Lymphoma, B Cell) 03/2005

Drug/Important Bio-Agent (IBA)

6	Ribonucleases (Ribonuclease)IBA 11/2017 - 06/2005
6	ranpirnase (Pannon)IBA 11/2017 - 06/2008
5	Proteins (Proteins, Gene)FDA Link 05/2015 - 05/2005
3	Pharmaceutical PreparationsIBA 11/2017 - 04/2013
3	Single-Chain AntibodiesIBA 10/2014 - 10/2003
3	Monoclonal AntibodiesIBA 02/2011 - 12/2003
2	Antineoplastic Agents (Antineoplastics)IBA 11/2017 - 06/2008
2	Rituximab (Mabthera)FDA Link 10/2016 - 03/2016
2	Immunoconjugates (Immunoconjugate)IBA 03/2016 - 01/2015
2	Immunoglobulin G (IgG)IBA 01/2015 - 01/2014
2	angiogeninIBA 05/2005 - 03/2005
1	porphine (porphin)IBA 11/2017
1	Photosensitizing Agents (Photosensitizers)IBA 11/2017
1	Interleukin-2 Receptors (IL 2 Receptor)IBA 03/2016
1	Tumor Biomarkers (Tumor Markers)IBA 05/2015
1	Immunoglobulin FragmentsIBA 05/2015
1	Immunoglobulins (Immunoglobulin)IBA 05/2015
1	Surface Antigens (Surface Antigen)IBA 01/2015
1	ErbB Receptors (EGF Receptor)IBA 10/2014
1	Antiviral Agents (Antivirals)IBA 04/2013
1	AntibodiesIBA 01/2009
1	Immunotoxins (Immunotoxin)IBA 01/2009

Therapy/Procedure

7	Therapeutics 10/2016 - 06/2008
2	Radioimmunotherapy 10/2016 - 03/2016
1	Aftercare (After-Treatment) 11/2017
1	Drug Therapy (Chemotherapy) 04/2013
1	Immunotherapy 03/2005